Effectiveness of synbiotic biocomplexes in correction of gut microbiocenosis disorders

The state of the gut microbiota largely determines the course of pathological processes in the human body. Currently, there is no doubt about the role of dysbiosis in the development and progression of many disorders, including intestinal infections, IBS, IBD, SIBO, diverticular disease, celiac disease, cancer, food intolerance, allergies, liver and pancreatic diseases, obesity, diabetes, metabolic syndrome, hematological, cardiological, genitourinary, rheumatological, neurological and neuropsychiatric. The development of tools that correct the imbalance of the gut microbiota is one of the most promising areas of the modern science. Methods for diagnosing disorders of the gut microbiota are also being improved. The importance and expediency of including agents that modulate the state of the gut microbiota in the complex therapy of many diseases is confirmed by numerous foreign and domestic studies. The evolution of probiotic products has progressed from single-strain formulations containing one type of microorganism to modern multi-strain synbiotic complexes that combine probiotics and prebiotics. The first generations of probiotics were primarily aimed at replenishing beneficial bacteria, whereas contemporary biocomplexes exert multi-level effects – they regulate the composition and activity of the gut microbiocenosis, promote the synthesis of necessary bacterial metabolites, improve intestinal barrier function, and modulate the immune response. This review article is devoted to evaluating the effectiveness of synbiotic biocomplexes Normoflorin L, B, and Д in the correction of gut microbiocenosis disorders in antibacterial therapy, functional bowel diseases, inflammatory bowel diseases, chronic pancreatitis, celiac disease, metabolic disorders and obesity, diseases of the ENT organs, dermatological and gynecological diseases.